Table 4 |
||||
|
Occurrence of DAIDS Grade 3/4 ALT/AST and hepatic serious adverse events (SAEs) among -LD and +LD TPV/r 500/200 mg BID patients |
||||
|
-LD patients1 |
+LD patients1 |
|||
|
|
||||
|
ALT/AST DAIDS >22 |
Hepatic SAE |
Hepatic SAE |
||
|
|
||||
|
Yes |
No |
Yes |
No |
|
|
|
||||
|
Yes |
3 |
107 |
1 |
29 |
|
|
||||
|
No |
6 |
970 |
4 |
141 |
|
|
||||
|
1Thirty-two patients had missing information and were unable to be classified into one of the two risk groups; none of these patients experienced a hepatic SAE. +LD = patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST Grade >1); -LD = patients with no apparent liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = aspartate aminotransferase; DAIDS = Division of AIDS; HBV = hepatitis B virus; HCV = hepatitis C virus; TPV/r = ritonavir-boosted tipranavir 2ALT/AST on treatment DAIDS Grade 3/4 |
||||
|
Mikl et al. BMC Infectious Diseases 2009 9:203 doi:10.1186/1471-2334-9-203 |
||||
